Completely agree with your sentiment.
Having worked in ICT with public health for a number of years, it takes a long time to get government to make decisions, particularly around new technologies and ways of working.
The value in this agreement continuing, is not the dollars in the door through licensing fees, but the evidence of the clinical utility and the clinical credibility, which will be worth much more in the long run.
This is sewing the seeds for widespread use in primary and tertiary healthcare settings across the country.
- Forums
- ASX - By Stock
- RAP
- Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic
Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-64
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 169 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)